on POXEL (EPA:POXEL)
Key Scientific Presentations on Imeglimin at ADA 2025
POXEL SA, a clinical stage biopharmaceutical company, announced five presentations on the therapeutic potential of Imeglimin at the 85th Scientific Sessions of the American Diabetes Association in Chicago. These presentations are expected to highlight Imeglimin, marketed as TWYMEEG® in Japan, particularly in its role in addressing type 2 diabetes and related conditions.
The presentations cover various topics, such as its impact on inflammation and fibrosis in diabetic kidney disease and its efficacy on insulin sensitivity alongside Metformin. The studies are supported by Sumitomo Pharma and feature contributions from prominent Japanese diabetes experts.
CEO Thomas Kuhn expressed satisfaction with the scientific community's enthusiasm for TWYMEEG® as a potent treatment option for diabetic patients.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all POXEL news